HealthTree Logo
search more_vert
person Sign In / Create Account
Study Results Show Selinexor (XPOVIO) with Bortezomib and Dex to be a Convenient and Effective Triplet Combination
Posted: Nov 13, 2020
Study Results Show Selinexor (XPOVIO) with Bortezomib and Dex to be a Convenient and Effective Triplet Combination image

Selinexor (XPOVIO)  was approved by the FDA in 2019 to be used with dexamethasone for patients who had relapsed five types of myeloma treatment. The BOSTON study results published today in The Lancet show that selinexor, weekly bortezomib (Velcade) and low-dose dexamethasone is an effective combination for multiple myeloma patients who have received 1-3 lines of prior therapy. 

The BOSTON study, performed at 123 sites in 21 countries, included 402 patients. Patients were split into two groups evaluating once-weekly selinexor in combination with once-weekly bortezomib (Velcade) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. This is the first trial to evaluate a once-weekly bortezomib schedule in relapsed multiple myeloma compared to a twice weekly comparator Vd arm.

Median progression free survival was 13.93 months with the selinexor/bortezomib/dex combination vs. 9.46 months with bortezomib/dex. Interestingly, peripheral neuropathy of grade 2 or higher was less frequent when selinexor was added (21%) compared to the doublet combination (34%). The mortality rate during the study was 24% in the selinexor/bortezomib/dex arm vs. 30% in the bortezomib/dex arm.

The FDA accepted a New Drug Application earlier this year for selinexor use in patients with only one prior line of therapy. These Phase III BOSTON study results paved the way for the FDA to set a march 19, 2021 date (based on the Prescription Drug User Fee Act, or PDUFA). 

Additional clinical trials such as the STOMP trial are underway to examine selinexor with other standard myeloma therapies. 

This once-weekly (all oral) option may be a new, effective and convenient treatment options for patients at earlier relapse. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube